Literature DB >> 1899855

A management approach to incompletely excised basal cell carcinomas of skin.

F F Liu1, E Maki, P Warde, D Payne, P Fitzpatrick.   

Abstract

There were 187 incompletely resected basal cell carcinomas (BCC) of skin referred to the Princess Margaret Hospital between 1970 and 1985. Median age at presentation was 62 years. The commonest location of these lesions was in the head and neck region (93%). One hundred twenty lesions were immediately treated: 119 were irradiated and 1 was excised. The remaining 67 lesions were managed expectantly. Follow-up time for the entire population ranged from 1 month to 17 years, with a median time of 2.7 years. The 5-year probability of remaining relapse-free in the group immediately treated was 91% versus 61% if managed expectantly (p = 0.0001). If only lateral margins were positive, the crude probability of local failure was 3/18 (17%), versus 9/27 (33%) if the deep margins were involved (p = 0.2). Once relapse occurred in the group of lesions treated expectantly, 17/20 (85%) of these relapses were salvaged by either radiation or surgery. The 10-year actuarial probability of local control for the lesions immediately treated and observed were similar: 92% and 90%, respectively (p = 0.5). An economic analysis revealed that immediate radiation treatment saved the health system only $223.00 per patient. Since there is no difference in the ultimate local control between these two approaches, and these elderly patients may be spared the morbidity of unnecessary treatments, it is suggested that a policy of observation may be adopted for basal cell carcinomas of skin which have been incompletely excised.

Entities:  

Mesh:

Year:  1991        PMID: 1899855     DOI: 10.1016/0360-3016(91)90052-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Incompletely excised basal cell carcinomas: Our guidelines.

Authors:  P Longhi; M Paola Serra; E Robotti
Journal:  Onco Targets Ther       Date:  2008-07-01       Impact factor: 4.147

Review 2.  Health economic evaluation of non-melanoma skin cancer and actinic keratosis.

Authors:  Mitchell K Higashi; David L Veenstra; Paul C Langley
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  Preservation of form and function in the management of head and neck skin cancer.

Authors:  Michael Poulsen; Bryan Burmeister; Dan Kennedy
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

4.  Treatment of facial Basal cell carcinoma: a review.

Authors:  Vanessa Smith; Shernaz Walton
Journal:  J Skin Cancer       Date:  2011-04-27

5.  Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study.

Authors:  M F Avril; A Auperin; A Margulis; A Gerbaulet; P Duvillard; E Benhamou; J C Guillaume; R Chalon; J Y Petit; H Sancho-Garnier; M Prade; J Bouzy; D Chassagne
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 6.  [Basal cell basal cell epithelioma of the face: surgical management, about 45 cases and review of the literature].

Authors:  Mohamed Amine Ennouhi; Abdenacer Moussaoui
Journal:  Pan Afr Med J       Date:  2014-09-25

7.  Incomplete excision of basal cell carcinoma (BCC) in the head and neck region: to wait, or not to wait?

Authors:  Jakub Miszczyk; Michał Charytonowicz; Tomasz Dębski; Bartłomiej Noszczyk
Journal:  Postepy Dermatol Alergol       Date:  2017-12-31       Impact factor: 1.837

8.  Recurrence rate of basal cell carcinoma with positive histopathological margins and related risk factors.

Authors:  Fernanda Lara; Jesus Rodriguez Santamaría; Luiz Eduardo Fabricio de Melo Garbers
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

Review 9.  Localized Non-melanoma Skin Cancer: Risk Factors of Post-surgical Relapse and Role of Postoperative Radiotherapy.

Authors:  Francesca Caparrotti; Idriss Troussier; Abdirahman Ali; Thomas Zilli
Journal:  Curr Treat Options Oncol       Date:  2020-10-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.